- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Daratumumab – November 2019
Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex®
Last updated
20 March 2020